ADC Therapeutics SA
ZYNLONTA
relapsed or refractory diffuse large B-cell lymphoma
Resolved
7days ago
Phase 1 readout · Jun 30, 2026
What's at stake
Phase 1 trial results for ZYNLONTA in relapsed or refractory diffuse large B-cell lymphoma are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Updated data from the LOTIS-7 Phase 1b clinical trial evaluating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/”